Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

Some large health systems are experimenting with selling their internal capabilities — such as IT support, revenue cycle management and call center operations — to smaller hospitals as a new ...

Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests ...

In today’s healthcare landscape, credibility doesn’t come from an agency logo. It comes from an idea that lands, a brand platform that manifests quickly, and results that speak for themselves.

Isaac Health, a startup specializing in cognitive care for Alzheimer’s dementia , raised $10.5 million in Series A funding to expand nationwide access to its platform. The company partners with ...

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” ...

The 2025 Benefits Sentiment Index, a survey of 120 benefit consultants to self-insured employers, focuses on healthcare navigation, GLP-1 drug coverage and AI trends for healthcare benefits.